EUROPEAN COMMISSION

Health and Food Safety Directorate General

sante.ddg2.g.5(2018)5173335

Standing Committee on
Section *Veterinary Medicinal Products*
24 SEPTEMBER 2018

CIRCABC Link: *https://circabc.europa.eu/w/browse/9a6fc441-0460-43d8-98ac-784374aa941a*

AGENDA

Section A Information and/or discussion

A.01 Opening and adoption of the agenda. (CS)

A.02 Follow-up to the discussion on diclofenac - Member State's update on the measures taken at national level, including in particular information on reported vulture deaths in the Member States that have diclofenac authorised and potential new authorisation given at national level. (AK)

A.03 Member State's update on the measures taken at national level, in particular suspension of the marketing authorisations of products for food-producing animals following a procedure under Article 30(3) of Directive 2001/82/EC for diethanolamine. (JP)

A.04 Maximum Residue Limits (MRLs) – update on implementing measures to the Regulation (EC) No 470/2009. (JP)

A.05 Update and information about International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) topics. (JP)

A.06 Stand of play and information about the revision of Directive 2001/82/EC. (CS)

A.07 AOB (CS)

Section B Draft(s) presented for an opinion

B.01 Exchange of views and possible opinion of the Committee on a draft Commission Implementing Decision granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Arti-Cell Forte - Chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells", a veterinary medicinal product. (CT)

(SANTE/3720784/2018)

Legal Basis: Regulation (EC) No 726/2004 - Art. 35

Procedure: Examination procedure